期刊文献+

肺功能异常对多发性骨髓瘤患者预后的影响 被引量:2

The Effect of Pulmonary Dysfunction on the Prognosis of Multiple Myeloma
下载PDF
导出
摘要 目的评估肺功能异常对多发性骨髓瘤(MM)患者预后的影响。方法对60例新诊断MM的患者,评估肺功能之后,进行30月随访,观察肺功能与患者预后的联系。结果27例患者(45.0%)有阻塞性或限制性肺功能缺损。阻塞性肺缺损患者的OS(生存率)明显低于限制性或肺功能正常患者。在多变量分析中,只有高危细胞遗传学和PEF和/或DLCO<65%是独立的预后影响因素。结论PEF和DLCO可作为新诊断MM患者OS重要预测指标,在初步评估中发挥作用。 Objective To evaluate the effect of pulmonary dysfunction on the prognosis of multiple myeloma(MM).Methods We prospectively performed PFTs in 60 newly diagnosed MM patients,before initiation of treatment,and we evaluated possible associations of lung function with their outcomes for 30 months.Results 27 patients(45.0%)had either obstructive or restrictive pulmonary function defects.The survival was significantly worse in those with obstructive pulmonary defect vs.those with restrictive or normal lung function.In the multivariate analysis,only the presence of high-risk cytogenetics and presence of either or both PEF and DLCO<65%of predicted were independent prognostic factors.Conclusion PEF and DLCO could be useful in the initial assessment of newly diagnosed MM patients as significant predictors of survival.
作者 刘喜 冯雅青 张利东 孟海涛 LIU Xi;FENG Ya-qing;ZHANG Li-dong;MENG Hai-tao(Department of Hematology,The Third People's Hospital of Datong,Shanxi Datong,037008)
出处 《山西大同大学学报(自然科学版)》 2020年第4期58-59,116,共3页 Journal of Shanxi Datong University(Natural Science Edition)
关键词 发性性骨髓瘤 肺功能 预后 multiple myeloma pulmonary function prognosis
  • 相关文献

参考文献2

二级参考文献18

  • 1周丽雅,李柯.急性胰腺炎的诊治要点 高淀粉酶血症[J].医师进修杂志,2004,27(9):1-3. 被引量:9
  • 2吴东,刘晓红.慢性高淀粉酶血症[J].中国实用内科杂志,2007,27(19):1552-1553. 被引量:7
  • 3BARTELINK I H, BREDIUS R G, BELITSER S V, et al. Asso- ciation between busulfan exposure and outcome in children re- ceiving intravenous busulfan before hematologic stem cell trans- plantation [ J]. Biol Blood Marrow Transplant, 2009, 15 ( 2 ) : 231-241.
  • 4RUSSELL1 J A, KANGARLOO S B. Therapeutic drug monitoring of busulfan in transplantation [ J ]. Curr Pharm Des, 2008, 14 (20) : 1936-1949.
  • 5LING Y C, ZHI F Z, MEI S, et al. Quantitative analysis of busulfan in human plasma by LC-MS-MS[ J]. Chromatographia, 2009, 70(11/12) : 1727-1732.
  • 6ABDEL-REHIM M, HASSAN Z, BLOMBERG L,et al. On-line derivatization utilizing solid-phase microextraction (SPME) for determination of busulphan in plasma using gas chromatography- mass spectrometry(GC-MS) [J]. Ther Drug Monit, 2003 , 25 (3) :400-406.
  • 7KRIVOY N, HOFFER E, LURIE Y, et al. Busulfan use in hem- atopoietic stem cell transplantation: Pharmacology, dose adjust- ment, safety and efficacy in adults and children [ J]. Curr Drug Saf, 2008, 3 ( 1 ) : 60-66.
  • 8HADJIBABAIE M, RAHIMIAN S, JAHANGARD-RAFSANJANI Z, et al. Population pharmacokineties of oral high-dose busulfan in adult patients undergoing hematopoietie stem cell transplanta- tion [J]. Darn,2011, 19(3) :216-223.
  • 9CHANDY M , BALASUBRAMANIAN P, RAMACHANDRAN SV , et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia-the role of busulfan phar- maeokineties in determining outcome [ J ]. Bone Marrow Transplanta- tion, 2005,36(10): 839-845.
  • 10SCHECHTER T, FINKELSTEIN Y, DOYLE J, et al . Pharma- eokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation [ J ]. Biol Blood Marrow Transplant, 2007, 13(3) : 307-314.

共引文献8

同被引文献22

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部